Dxcover, a Glasgow-based oncology diagnostics company, plans to release its brain cancer blood test in Europe by 2025 to aid in the triage of symptomatic patients. The test uses infrared light on blood samples, with a machine-learning algorithm predicting cancer presence.
In 2021, the test demonstrated 91% sensitivity for detecting glioblastoma, a common aggressive brain tumor. While Dxcover’s initial focus is on single-tumor detection, it may compete with firms like GRAIL in the U.S. for early cancer detection in healthy individuals.